Salute e Benessere

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group…

RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance. RICHMOND, Va. , Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance. Comment byMark Crossley, CEO of Indivior PLC "We are seeing faster than expected initial adoption of the competitive product to SUBLOCADE...
PR Newswire
10/10/2024

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T…

Company to hostconference call and webcasttoday, October 10, at 9:00 am EDT/3:00 pm CESTCompany announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a...
Nasdaq GlobeNewswire
10/10/2024

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of…

The Phase 2 trial (NCT06504147) is a randomized controlled study assessing the efficacy and safety of Radspherin® in patients with peritoneal metastasis from ovarian cancer. The primary objective is to compare PFS between patients who receive Radspherin® after complete surgical resection following pre-operative chemotherapy, and patients who only undergo pre-operative chemotherapy and surgery. The study is being conducted at six centers in the US, UK, Norway, Spain and Belgium. Positive Phase…
PR Newswire
10/10/2024

European Medicines Agency Confirms Acceptance of Marketing Application for…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab).“EMA acceptance marks an important step towards making AVT03 available to patients and caregivers in Europe,” said Joseph McClellan, Chief Scientific Officer of...
Nasdaq GlobeNewswire
10/10/2024

BVA Survey by IntyEssentials Reveals The Extent of Sexual Pain Among Women in…

The study highlights the frequency and severity of pain during intercourse in the female population in France. Almost 47% of women say they sometimes or often experience pain during penetrative sex, while 33% report pain after intercourse. Of those affected, 40% rate their pain as 6 or more on a scale of 1 to 10, underlining the severity of such pain. The study highlights the frequency and severity of pain during intercourse in the female population inFrance. Almost47% of women say they...
PR Newswire
10/10/2024

Implantica announces highly successful 2024 American Foregut Society meeting…

Implantica is actively working on the FDA approval process to bring RefluxStop® to the US market with the PMA filing of the second module (of three) expected in the near-term. The RefluxStop® procedure was at the forefront of the new innovation discussions at the AFS meeting. Implantica is actively working on the FDA approval process to bring RefluxStop® to the US market with the PMA filing of the second module (of three) expected in the near-term. The RefluxStop® procedure was at the…
PR Newswire
10/10/2024

AB Science: Revenues for the first half of 2024 and update on AB Science's…

PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform:Ongoing re-examination by EMA and Health Canada of the marketing authorisation application for masitinib in amyotrophic lateral sclerosis (ALS)Update on the development of masitinib in progressive forms of multiple sclerosis following the ECTRIMS 2024 conferencePositive results from the phase 2 study of masitinib...
Nasdaq GlobeNewswire
10/10/2024

Pharming Group to report third quarter 2024 financial results on October 24

Leiden, the Netherlands, October 10, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024. To participate in the conference call, please register in advance using the link below. Once registered,...
Nasdaq GlobeNewswire
10/10/2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer…

10 October Avacta Group plc(“Avacta” or “the Group” or “the Company”) Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium LONDON, UK, 10 OCT 2024,Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments, today announced that the Company will present new preclinical data on two breakthroughs in the pre|CISION™ platform in poster sessions at the 2024...
Nasdaq GlobeNewswire
10/10/2024

NIPPON EXPRESS HOLDINGS Completes Acquisition of Shares in SH HoldCo GmbH Making…

Acquisition of Shares of SH HoldCo GmbH to become a Fully-Owned Subsidiary: https://pdf.irpocket.com/C9147/EAzE/VVeN/q42N.pdf Acquisition of Shares of SH HoldCo GmbH to become a Fully-Owned Subsidiary:https://pdf.irpocket.com/C9147/EAzE/VVeN/q42N.pdf Overview of Simon Hegele Group: https://pdf.irpocket.com/C9147/EAzE/VVeN/bK8X.pdf Photo 1: First from left of photo:Mamoru Akaishi/ Director and Executive Officer / NXHD; second from left:Stefan Ulrich/ Simon Hegele Group...
PR Newswire
10/10/2024

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China…

Allschwil, Switzerland, October 10, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch,...
Nasdaq GlobeNewswire
10/10/2024

Pharming Group announces start of Phase II clinical trial of leniolisib for…

Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytesPIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency and PTEN deficiency, with prevalence approximately five times that of APDS Clinical trial being conducted at the National Institutes of Health (NIH) Leiden, the Netherlands, October 10, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam:...
Nasdaq GlobeNewswire
10/10/2024

Roche obtains CE certification for the first companion diagnostic to identify…

The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer who may benefit from a targeted treatment option. CLDN18.2 is an emerging biomarker in gastric and GEJ cancers and helps predict the likelihood of response to targeted therapy.As the leader in companion diagnostics, Roche continues to build on its commitment to improve personalised healthcare to enable better...
Nasdaq GlobeNewswire
10/10/2024

Fagron reports outstanding third quarter 2024 performance with 12.1% revenue…

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlookFagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2024. Key Highlights Continued topline momentum with 12.1% reported revenue growth (15.7% at CER) and 12...
Nasdaq GlobeNewswire
10/10/2024

Valneva Hosts Investor Day in New York City

Live event and webcast TODAY at 10 AM ETSaint Herblain (France), October 10, 2024 – Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an investor day today in New York City to discuss the Company's key value drivers over the next 12-18 months and beyond. Valneva's Chief Executive Officer Thomas Lingelbach, Chief Financial Officer Peter Bühler, and other members of the Company's senior leadership team will highlight the Company's substantial...
Nasdaq GlobeNewswire
10/10/2024

ClaroNav Dental Announces CE Mark: EU Marketing Authorization for MicronMapper

MicronMapper is ClaroNav Dental's next-generation photogrammetry system designed to streamline and improve the dental implant workflow. With a lightweight, easy-to-use design, and advanced 3D photogrammetry capabilities, MicronMapper enables dental professionals to capture highly detailed and precise implant positions resulting in more predictable outcomes and a high level of patient satisfaction. It significantly reduces the need for traditional, time-consuming methods, such as verification…
PR Newswire
10/10/2024

Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis…

Key Takeaways from the Cell and Gene Therapy in Parkinson's Disease Pipeline Report Key Takeaways from the Cell and Gene Therapy in Parkinson's Disease Pipeline Report Request a sample and discover the recent advances in cell and gene therapy in Parkinson's disease drug treatment @ Cell and Gene Therapy in Parkinson's Disease Pipeline Report The cell and gene therapy in Parkinson's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of...
PR Newswire
09/10/2024

Information on the total number of voting rights and shares

REGULATED INFORMATIONInformation on the total number of voting rights and sharesMont-Saint-Guibert(Belgium), October 9, 2024 , 10:35 pm CET / 4:35 pm ET –In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,423,111.21 Total number of securities carrying voting rights: 37,389,015 (all ordinary...
Nasdaq GlobeNewswire
09/10/2024

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), October 9, 2024 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.BlackRock, Inc.On October 7, 2024, Nyxoah received a transparency notification from BlackRock,...
Nasdaq GlobeNewswire
09/10/2024

Innocan Pharma Celebrates Dr. Joseph Pergolizzi's Recognition Among Stanford…

"We are incredibly proud of Dr. Pergolizzi's well-deserved recognition as one of the most-cited scientists worldwide," said Iris Bincovich, CEO of Innocan Pharma. "His recognition as part of Stanford University's top 2% is a reflection of his dedication to advancing medical research. His expertise has been pivotal in advancing our R&D efforts and aligning them with FDA regulatory pathways. I congratulate Dr. Pergolizzi on this outstanding honor and look forward to continuing…
PR Newswire
09/10/2024

Ipsen - September 2024 - Monthly information relative to the total number of…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)30 September 202483,814,526Gross total* of...
Nasdaq GlobeNewswire
09/10/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of September 30, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (October 9, 2024 - 6:00 pm)– As of September 30, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and...
Nasdaq GlobeNewswire
09/10/2024

PHAXIAM Therapeutics announces the validation of a new investigator-initiated…

A Phase 2 study sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)Evaluation of the efficacy of a local treatment with PHAXIAM's anti- S. aureusphages added to the standard treatment by surgery and antibiotics 80 patients to be enrolled in 27 French clinical centersValidation of the study protocol by the ANSM expected in H1 2025 Lyon (France), October 9, 2024 – 06:00pm CEST - PHAXIAM Therapeutics...
Nasdaq GlobeNewswire
09/10/2024

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of…

Centivax's Chief Executive Officer, Jacob Glanville, said, "We are thrilled to announce BioCina as our Master Cell Bank manufacturing partner for the first phase of manufacturing our universal influenza vaccine. BioCina's exemplary expertise and track record in mRNA/LNP MCB, combined with their state-of-the-art facilities, aligns perfectly with Centivax's commitment to innovation and quality. This partnership enables us to leverage BioCina's expertise to ensure the highest standards of…
PR Newswire
09/10/2024
Altri  Comunicati